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Abstract
Introduction: Electrical stimulation could provide an alternative method for preventing venous thromboembolism in
stroke patients. The purpose of this preliminary study was to explore the effects of electrical stimulation and intermit-
tent pneumatic compression on enhancing lower limb venous return in healthy and chronic stroke patients and also to
evaluate patient and nurse satisfaction.
Methods: We investigated the effectiveness of two electrical stimulation devices: Geko (Firstkind Ltd, High Wycombe,
UK) and Orthopaedic Microstim 2V2 (Odstock Medical Ltd, Salisbury, UK); and one intermittent pneumatic compres-
sion device: Huntleigh Flowstron Universal (Huntleigh Healthcare Ltd, Cardiff, UK). We recruited 12 healthy and 5
chronic stroke participants. The devices were fitted sequentially, and Doppler ultrasound measurements were taken.
Eight patients and nurses were also recruited for a separate usability evaluation.
Results: The electrical stimulation devices emulated the blood flow characteristics of intermittent pneumatic compres-
sion in both healthy and stroke participants provided that the intensity of electrical stimulation was sufficient. Patients
and nurses also felt that the electrical stimulation devices were acceptable.
Conclusions: Electrical stimulation may offer benefit as an alternative method for venous thromboembolism prevention
in stroke patients. The apparent benefit is sufficient to warrant further investigation in a full powered randomised
controlled trial.
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Introduction
Venous thromboembolism (VTE) is a major problem in
the acute phase of a stroke. Deep vein thrombosis
(DVT) has been detected in up to 42% of stroke
patients in hospital, and pulmonary embolism accounts
for up to 25% of early mortality after an acute
stroke.1–3 Graduated compression stockings are not
an eﬀective method of reducing the risk of DVT after
stroke, and guidelines suggest that anticoagulants
should only be used for patients with a low risk of
bleeding and a high risk of thromboembolism.4,5
Intermittent pneumatic compression (IPC) has been
shown to be eﬀective, but patient compliance is
low.2,6 IPC consists of stockings which are secured
around the calf, or the calf and thigh, and then inﬂate
and deﬂate to compress the legs. This is thought to
lower the risk of DVT by reducing venous stasis.7 A
multi-centre, randomised, controlled trial demonstrated
that thigh length IPC is an eﬀective method of reducing
the risk of DVT in the acute phase after stroke, but
adherence was a major issue.2 Poor adherence to
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IPC has been recognised as a major limitation for
some time.6
Electrical stimulation (ES) could be used as an
alternative method of reducing the risk of DVT after
stroke. Intermittent contraction of the muscles that
dorsiﬂex the foot through ES of the common peroneal
nerve is thought to compress the leg veins and
improve venous return in a similar way to the skele-
tal-muscle pump action whilst walking. Several studies
have demonstrated that ES is able to increase venous
velocity and ﬂow in healthy participants.8–15 Two
recent systematic reviews demonstrated that there is
moderate quality evidence to support ES over no
prophylaxis in a clinical setting for preventing
VTE.16,17 However, how patient selection inﬂuences
eﬃcacy and the most eﬀective device and protocol is
unknown. In particular, there is a dearth of experi-
mental and clinical studies in the stroke population,
who may have important diﬀerences in vasculature
but could potentially beneﬁt from ES as a method
of VTE prophylaxis.
ES devices are battery powered and attach to the
patient’s leg with self adhesive electrodes. Previous stu-
dies have shown that Geko (FirstKind Medical Ltd,
UK), a single-use disposable ES device with an inte-
grated battery, signiﬁcantly increases venous blood
ﬂow in the lower limb of healthy participants
(Figure 1(a)).18 An alternative reusable ES device, the
Orthopaedic Microstim 2V2 (Odstock Medical Ltd,
UK), has a reusable powered controller component
with disposable surface electrodes and would be a less
expensive option if used for multiple days (Figure 1(b)).
This preliminary study aimed to demonstrate the
eﬀect of Geko, Orthopaedic Microstim 2V2 and IPC
on lower limb venous return in healthy and stroke-
aﬀected participants. We also sought to evaluate
patient and nurse satisfaction with the ES devices and
determine whether there would be any beneﬁt over
existing stroke VTE prophylaxis strategies.
Methods
Blood flow study
Participants. We recruited 12 healthy volunteers and a
convenience sample of ﬁve existing users of ES for the
correction of dropped foot caused by a stroke. All par-
ticipants were over the age of 18, mobile enough to
transfer to a bed safely and able to provide informed
consent. The healthy participants had no history of car-
diovascular disease whereas the existing users of ES
were >6 months post stroke. This part of the study
was approved by the University of Southampton
Research Ethics committee (ERGO reference numbers
10652 and 23157).
ES interventions. We used two diﬀerent types of ES:
Geko (FirstKind Medical Ltd, UK) and Orthopaedic
Microstim 2V2 (Odstock Medical Ltd, UK). Geko is a
small, disposable self-adhesive band containing two
electrodes and a stimulator with an integral battery
which provides approximately 24 h of operation
before the whole unit is replaced. It is applied to the
lower leg on the skin overlying the common peroneal
nerve (Figure 1(a)). It pulses a current of 27 mA at a
frequency of 1Hz, which results in a single ankle dorsi-
ﬂexor muscle twitch every second. Pulse width can be
varied between 7 settings (70, 100, 140, 200, 280, 400
and 560 ms) and is adjusted to produce a slight visible
movement of the foot. The Orthopaedic Microstim 2V2
consists of a stimulator box and two leads which are
connected to two multiple use self-adhesive electrodes
placed over the common peroneal nerve (Figure 1(b)).
Current intensity, pulse width and frequency can be
varied. We used a pulse width of 300 ms and a frequency
of 40Hz, delivering 20 pulses within half a second,
every two seconds. We observed, during our prepara-
tory work for this study, that stroke-aﬀected partici-
pants required higher levels of ES to increase blood
ﬂow than healthy participants. Therefore, two diﬀerent
Figure 1. ES devices (a) Geko and (b) Orthopaedic Microstim 2V2.
ES: electrical stimulation.
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Orthopaedic Microstim 2V2 levels of stimulation were
used in the stroke-aﬀected group. A low setting,
Microstim low (MSL), deﬁned as the minimum current
required to produce a slight visible movement of the
foot; and a high setting, Microstim high (MSH),
deﬁned as the minimum current required to reproduce
the patient’s full range of passive dorsiﬂexion. Taking
the ankle through passive range of dorsiﬂexion is closer
to the movement achieved while walking. Walking is
believed to cause the muscle pump eﬀect and so it is
likely that stretching of the calf muscle in this way
pushes blood out of the compartment. Passive range
of dorsiﬂexion was determined by the researcher at
the start of the test using a manual goniometer. The
two diﬀerent levels of stimulation were used to provide
dose-ranging information and inform future work.
IPC intervention. The IPC comparator was the Huntleigh
Flowtron UniversalTM (Huntleigh Healthcare Ltd,
UK). The device runs a compression cycle of 1min,
which consists of 13 s of compression and 47 s of relax-
ation. The inﬂation pressure was 40mmHg. Knee
length stockings were used in the healthy group, in
accordance with previous studies comparing IPC and
ES haemodynamics,15,18 whilst thigh length stockings
were used in the stroke-aﬀected group because of sub-
sequent clinical evidence demonstrating that thigh
length IPC reduces the risk of VTE in the acute
stroke.2 The devices were applied unilaterally (to the
aﬀected leg in stroke participants).
Study design. Lower limb venous ﬂow was the primary
outcome as measured by duplex ultrasound of the
superﬁcial femoral vein. Three interventions were
applied to each subject: Geko, Microstim 2V2 and
IPC. The order of interventions was randomised
according to a pre-determined randomisation schedule
(online Appendix D). There was a 5-min rest period
before each intervention in order to allow venous ﬂow
to return to baseline. Measurements were taken at the
end of this period in order to identify any baseline vari-
ability. Each intervention was applied for eight min-
utes, during which the ﬁrst ﬁve minutes were
‘conditioning’ and measurements were taken in the
ﬁnal three minutes. After each intervention, partici-
pants were asked to rate discomfort levels using a
visual analogue scale (VAS), which involved marking
the level of pain on a 100mm line marked with ‘no
pain’ at one end and ‘worst pain imaginable’ at the
other end. VAS is a standard method for assessing
pain and its application was standardised within this
study. A Likert scale was also devised to score per-
ceived discomfort where 0¼ ‘no sensation’, 1¼ ‘mild
sensation’, 2¼ ‘moderate sensation’, 3¼ ‘mild discom-
fort’, 4¼ ‘moderate discomfort’ and 5¼ ‘severe
discomfort’. Several similar studies have used VAS
and Likert scales to measure pain and discomfort asso-
ciated with ES and IPC.14,18
Ultrasound measurements. All ultrasound measurements
were taken at the superﬁcial femoral vein by a single
accredited vascular sonographer. Participants were in a
sitting position with their knees extended on a two-sec-
tion examination couch with the back at 45 (Fowler’s
position). This is a position that may be used for nur-
sing a patient in hospital following an acute stroke.
Their head was supported by a pillow, and their legs
were exposed to the upper thigh. Measurements were
taken at the mid thigh superﬁcial femoral vein (short
axis view) using a 4–9MHz linear array transducer and
pulsed wave (4MHz) colour-ﬂow duplex ultrasound
(Siemens Acuson S2000; Siemens AG, Erlangen,
Germany). The instrument output was 70 dB and,
with this setup, the maximum depth of measurement
was 9 cm. The position of the ultrasound probe was
marked on the skin for consistency.
Data analysis. We studied vessel diameter, volume ﬂow,
time-averaged mean velocity (TAMV) and peak velocity
over a 14 s period. Volume ﬂow (ml/min) is the product of
the TAMV and the cross-sectional area of the blood
vessel. TAMV (cm/s) is the weighted mean velocity
during each time interval averaged out over the trace as
an estimate of true mean velocity. Peak velocity (cm/s) is
the maximum velocity reached during the trace. For the
IPC device, measurements were taken three times in both
the inﬂation and deﬂation period in order to calculate the
average volume ﬂow over one minute.
Statistical analysis. The baseline measurements acted as a
reference range. Repeat measurements were averaged.
The sample size was small, and so the results were
assumed not to be normally distributed. The raw data
was described using medians and inter-quartile ranges.
We tested the null hypothesis that the distributions of
volume ﬂow, TAMV and peak velocity were the same
by using the Kruskal–Wallis test with a post hoc
Mann–Whitney test and Bonferroni correction. A p
value of 0.05 was considered statistically signiﬁcant.
The outcome measures were also expressed as a per-
centage change from baseline.
User satisfaction study
Participants. We recruited eight patients and eight nurses
on the stroke ward at Salisbury District Hospital for the
ward evaluation. Patients were admitted with an acute
stroke, over the age of 18 and able to provide informed
consent. Exclusion criteria were presence of a cardiac
pacemaker or implanted deﬁbrillator, and uncontrolled
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epilepsy. There was no overlap between the participants
in the blood ﬂow and user satisfaction studies. This part
of the study was approved by the Salisbury District
Hospital Patient and Public Involvement Committee.
We asked the patients to wear each activated device
(Geko, Orthopaedic Microstim 2V2 and IPC) sequen-
tially on one leg for 20min whilst reclining in bed. The
stimulation parameters were the same as those used in
the blood ﬂow study. We asked for feedback in the
form of a ﬁve-question, semi-structured interview/ques-
tionnaire regarding comfort, mobility and overall sat-
isfaction. The order of interventions was randomised
according to a predetermined randomisation schedule
(online Appendix D). There was a time interval of up to
5min between interventions.
We asked the nurses to observe a demonstration of
all three devices and give feedback in the form of a
nine-question, semi-structured interview/questionnaire
regarding ease of use, safety concerns and anticipated
eﬀect on rehabilitation and care. Responses were in the
form of a Likert Scale and attributed a value between 1
and 5 (1 being the least desirable response and 5 being
the most desirable response). The diﬀerence from the
worst possible score for each question was used to gen-
erate a satisfaction score, which was expressed as a per-
centage of the best possible score. The questionnaires
were developed ‘in house’. For details of individual
questions, see online appendices A and B.
Results
Blood flow study
We recruited 12 healthy (nine male and three
female, age range 24–68) and ﬁve stroke-aﬀected par-
ticipants (two male and three female, median age 81,
age range 58–87). Flow volume, TAMV and peak ﬂow
velocity at baseline and in response to each intervention
are shown in Table 1. MSL produced the greatest
median volume ﬂow and TAMV and a signiﬁcantly
greater TAMV and peak ﬂow compared to baseline in
healthy participants. MSH produced the greatest
median ﬂow volume, TAMV and peak velocity, and
both MSH and IPC produced a signiﬁcantly greater
peak ﬂow velocity compared to baseline in stroke-
aﬀected participants. There were no signiﬁcant diﬀer-
ences between devices.
There were no discernible diﬀerences in baseline
measurements before each intervention. The highest
percentage change in ﬂow volume and TAMV was
achieved by MSH in the stroke group and MSL in
the healthy group (Figure 2). IPC produced the greatest
percentage increase in peak velocity in both groups.
There was a much lower percentage increase in ﬂow
volume, TAMV and peak velocity in response to
MSL and Geko in the stroke group compared to the
healthy group.
Table 1. Blood flow volumes, TAMV and peak flow velocities in healthy (n¼ 12) and chronic stroke participants (n¼ 5).
Baseline Geko MSL MSH IPC p-Value
Pairwise
comparisons
Flow volume (ml/min)
Stroke 94 (81–100) 76 (69–110) 87 (81–89) 150 (120–260) 98 (92–98) 0.076 –
Healthy 92 (79–98) 100 (92–130) 130 (100–160) – 110 (81–140) 0.080 –
TAMV (cm/s)
Stroke 3.2 (3.0–3.4) 3.3 (3.0–3.6) 3.4 (3.2–3.4) 5.6 (4.4–7.3) 3.1 (2.2–4.1) 0.073 –
Healthy 2.3 (2.2–2.5) 3.0 (2.6–3.6) 3.5 (2.8–3.9) – 3.1 (2.2–3.7) 0.034 MSL-baseline
(p¼ 0.045)
Peak flow velocity (cm/s)
Stroke 10 (9.4–11) 13 (11–14) 13 (13–14) 32 (26–61) 31 (29–34) <0.01 MSH-baseline
(p< 0.01)
IPC-baseline
(p< 0.01)
Healthy 8.0 (8.2–9.1) 13 (10–16) 19 (15–23) – 25 (15–30) <0.01 MSL-baseline
(p< 0.01)
IPC-baseline
(p< 0.01)
Values are presented as median (inter-quartile range). p-Values represent the results of six separate Kruskal–Wallis tests. Pairwise comparisons refer to
post hoc Mann–Whitney tests. Significance values have been adjusted by the Bonferroni correction for multiple tests. Significant results only are
displayed.
MSL, Orthopaedic Microstim 2V2 low setting; MSH, Orthopaedic Microstim 2V2 high setting; IPC, intermittent pneumatic compression; TAMV, time
average mean velocity.
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Responses showed no signiﬁcant diﬀerence in dis-
comfort between the devices using the VAS or Likert
Scale devised for this study.
User satisfaction survey
Eight patients (four male and four female) and eight
nurses (two male and six female) completed the device
evaluation. The median patient age was 77 (range 31–
94). The results of the evaluation are presented in
Figure 3. We found that the Geko had the best average
patient satisfaction score (89%), followed by the
Orthopaedic Microstim 2V2 (84%) and then IPC
(66%). Similarly, the Geko had the best nurse satisfac-
tion score (85%), followed by the Orthopaedic
Microstim 2V2 (65%) and then IPC (31%). There
were signiﬁcant diﬀerences between devices in both
patient and nurse satisfaction scores (p< 0.01). For
patients, post hoc analysis showed signiﬁcantly lower
satisfaction with IPC, but no diﬀerence between the ES
devices; whereas for nurses, there was a signiﬁcant dif-
ference in satisfaction between all three devices.
Eﬀect on mobility seemed to be the main area where
nurses and patients felt thatGeko outperformed the other
two devices. None of the patients or nurses felt that Geko
interfered with their ability to move or engage in rehabili-
tation, and the majority of nurses felt that it would not
increase the risk of falls. In contrast, several patients and
nurses felt that Orthopaedic Microstim 2V2 and IPC
would interfere with their ability to move or engage in
rehabilitation. The majority of nurses also felt that both
devices would increase the risk of falls. Nurses felt that
Geko was easier to apply than the other two devices and
would have less of an impact on personal care. To see the
individual questions and breakdown of the scores, please
see online appendices A to C.
Discussion
It is thought that IPC reduces the risk of VTE in stroke-
aﬀected patients by preventing venous stasis.2 As such,
venous blood ﬂow is often used as a surrogate for the
prevention of VTE and to add value to new VTE pre-
vention technologies. Our small preliminary study sug-
gests that ES is as eﬀective as IPC at improving blood
ﬂow, TAMV and peak velocity in both healthy individ-
uals and those with a chronic stroke, but the intensity
of ES must be suﬃcient. The level of contraction pro-
duced by Geko and MSL seemed to produce little
increase in blood ﬂow in chronic stroke participants
from baseline, whereas higher intensity MSH produced
a greater increase in blood ﬂow, TAMV and peak vel-
ocity. On the other hand, Geko and MSL seemed to be
suﬃcient to increase blood ﬂow in healthy participants.
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Figure 2. Percentage increase in blood flow from baseline. The bottom of the box represents the 25th percentile, the centre of the
box represents the median and the top of the box represents the 75th percentile. The vertical lines represent the extremes of values.
TAMV, time average mean velocity; MSL, Orthopaedic Microstim 2V2 low setting; MSH, Orthopaedic Microstim 2V2 high setting; IPC,
intermittent pneumatic compression.
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Changes in ES intensity and biological variation may
explain conﬂicting evidence on the relationship between
ES and the incidence of VTE reported in the review by
Hajibandeh et al.19
We observe that the ES devices had a greater impact
on venous ﬂow and TAMV than IPC, whereas IPC has
more of an impact on peak velocity, although there
were no signiﬁcant diﬀerences between devices. This
ﬁnding is compatible with that of Jawad et al.18 who
compared the eﬃcacy of Geko against two diﬀerent
IPC devices (below knee Huntleigh Flowtron
Universal and Kendall SCD Express) at enhancing
lower limb blood ﬂow in the superﬁcial femoral vein
in 10 healthy people. At threshold setting (the minimum
setting to elicit a minor muscular contraction in both
the calf and the foot), Geko increased venous ﬂow by
14% whereas the Huntleigh Flowtrons decreased ﬂow
by 4%. The optimal blood ﬂow characteristics for pre-
venting VTE are unknown but there is some suggestion
that IPC devices with the highest peak velocities also
have the highest incidence of VTE.20
There is a dearth of data comparing the compliance
and tolerability of ES with other forms of mechanical
VTE prophylaxis in stroke rehabilitation therapy.17 This
study is the ﬁrst to evaluate patient and nurse satisfac-
tion of ES and IPC to our knowledge. Our preliminary
results show that both patients and nurses have positive
initial impressions of ES devices, highlighting several
advantages over IPC. Comfort, adherence, mobility
and independence are all important factors for stroke
rehabilitation, so choice of VTE prevention could have
a major impact on adherence and recovery.
Study limitations
Whilst the results are promising, there are several meth-
odological limitations to this preliminary study. We
used a very small convenience sample of healthy and
chronic stroke participants who were existing users of
ES. No power calculations were used in the design of
this study, so the results should be interpreted with
caution. We did not attempt to match the baseline char-
acteristics of healthy and stroke participants which
limits comparison between the two groups. Moreover,
the existing users of ES would have had some condi-
tioning, which may have increased muscle strength
compared to unconditioned users. They were also
>6months post stroke and therefore were likely to
have variable levels of ankle stiﬀness or calf spasticity,
which would require diﬀerent levels of muscle contrac-
tion to produce dorsiﬂexion in comparison to those
who have had an acute stroke. The generalisibility of
the results to the acute stroke population is therefore
questionable. We did not assess the eﬀect of fatigue
during ES, which may also aﬀect its eﬃcacy. We did
not study blood ﬂow in the period following ES.
The device evaluation was conducted within a single
stroke unit, and the number of patients and nurses
completing the clinical comparison were small.
Nurse’s views may have been biased by previous IPC
experience, and it is possible that only patients and
nurses with a very positive or negative experience vol-
unteered to take part in the study. The questionnaires
were not validated and may be subject to error.
Conclusion
This study indicates that ES may be an eﬀective and
acceptable intervention for preventing VTE in healthy
and chronic stroke patients. However, for ES to have
an eﬀect on blood ﬂow comparable to IPC in those with
a chronic stroke, the intensity should be suﬃcient to
move the ankle through all or part of its passive
range of dorsiﬂexion. There appears to be suﬃcient
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Figure 3. Satisfaction score distribution. Figure 2(a) represents the nurse’s average satisfaction score, and Figure 2(b) represents the
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IPC, intermittent pneumatic compression.
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beneﬁt to warrant further investigation in a full pow-
ered randomised controlled trial.
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